[Future therapies for metabolic bone diseases. New concepts and targets].

作者信息

Nemec K, Schubert-Zsilavecz M

机构信息

Institut für Pharmazeutische Chemie Marie-Curie-Str. 9 60439 Frankfurt.

出版信息

Pharm Unserer Zeit. 2001;30(6):548-52. doi: 10.1002/1615-1003(200111)30:6<548::AID-PAUZ548>3.0.CO;2-5.

DOI:10.1002/1615-1003(200111)30:6<548::AID-PAUZ548>3.0.CO;2-5

PMID:11715689

Abstract

摘要

相似文献

[Future therapies for metabolic bone diseases. New concepts and targets].

Pharm Unserer Zeit. 2001;30(6):548-52. doi: 10.1002/1615-1003(200111)30:6<548::AID-PAUZ548>3.0.CO;2-5.

[Osteoclastogenesis inhibitory factor (OCIF)/OPG (a novel therapeutic candidate for the treatment of metabolic bone diseases)].

Nihon Rinsho. 2002 Mar;60 Suppl 3:679-87.

[The cytokine system of bone tissue].

Ugeskr Laeger. 2005 Feb 21;167(8):874-8.

Genetic control of bone remodeling--insights from a rare disease.

N Engl J Med. 2002 Jul 18;347(3):210-2. doi: 10.1056/NEJMe020066.

Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice?

J Endocrinol Invest. 2005;28(10 Suppl):14-22.

The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.

J Rheumatol. 2004 May;31(5):844-6.

Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases.

J Clin Endocrinol Metab. 2000 Jul;85(7):2355-63. doi: 10.1210/jcem.85.7.6702.

[The pathophysiology of osteoporosis/osteopenia in gene mutant mice].

Clin Calcium. 2006 Feb;16(2):311-18.

[Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?].

An Med Interna. 2002 Aug;19(8):385-88.

Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice.

Bone. 2004 Apr;34(4):656-64. doi: 10.1016/j.bone.2003.12.006.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验